Brigatinib

Category: Cancer



Brigatinib Overview

Brigatinib (INN;[1] marketed as Alunbrig) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.[2] Brigatinib acts as both a anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.[3] Contents...

Read more Brigatinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brigatinib

Recent Brigatinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Brigatinib
  • Tablet: 180mg, 30mg, 90mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Brigatinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA